NEW YORK – Hitachi and Centre Léon Bérard (CLB), a cancer center in Lyon, France, said Thursday that they have partnered on research and development aimed at improving the efficiency and efficacy of cancer diagnosis and treatment.
As part of the agreement, they have jointly established a new research laboratory. The Hitachi Lyon Lab, housed at CLB, will study novel ways to detect cancer by applying artificial intelligence to medical imaging and to predict response to radiation therapy using genomic and transcriptomic data.
The partners said they would apply CLB's clinical expertise and patient data and Hitachi's know-how in diagnostic imaging and AI to develop diagnostic imaging technologies to detect cancer sites and to help radiologists improve diagnosis from CT and MRI scans. In addition, they plan to identify biomarkers from genomic data to predict response to radiation treatment and prognoses after such treatment.